However, for CML patients in the chronic phase (CP), deletion of ABL1-BCR did not result in poor response to imatinib or lower rates of either complete cytogenetic or major molecular responses (Quintas-Cardama et al., 2011; Svabek et al., 2018). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.